CSTONE PHARMA-B(02616): ACAAI 2025 | CS2015 (OX40L/TSLP bispecific antibody) made its first international academic appearance.

CSTONE PHARMA-B (02616) announced that the company will present one of its pipeline candidates, CS2015 (OX40L/TSLP bispecific antibody), at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in 2025 in the form of an electronic poster and oral presentation. ACAAI is one of the most influential academic conferences in the global allergy, asthma, and immunology field, attracting experts and scholars from around the world to discuss the latest research findings. This will be the first international appearance of CS2015 at an academic conference, and the abstract and full content of the electronic poster are now officially available on the ACAAI website. CS2015 adopts an asymmetric molecular structure, targeting both OX40L and TSLP, two key regulatory factors in type 2 inflammation that have been clinically validated to effectively block inflammation. The molecule utilizes a mutated Fc to weaken its binding with FcR and prolong its circulating half-life in the body, ultimately optimizing pharmacokinetic (PK) characteristics and supporting long dosing intervals. The excellent molecular stability of CS2015 provides assurance for the development of high-concentration subcutaneous formulations. Additionally, its outstanding developability lays the foundation for high yield and large-scale production.